|
1
|
Friedl P and Alexander S: Cancer invasion
and the microenvironment: plasticity and reciprocity. Cell.
147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mohawk JA, Green CB and Takahashi JS:
Central and peripheral circadian clocks in mammals. Annu Rev
Neurosci. 35:445–462. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takahashi JS, Hong HK, Ko CH and McDearmon
EL: The genetics of mammalian circadian order and disorder:
implications for physiology and disease. Nat Rev Genet. 9:764–775.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rafnsson V, Tulinius H, Jónasson JG and
Hrafnkelsson J: Risk of breast cancer in female flight attendants:
a population-based study (Iceland). Cancer Causes Control.
12:95–101. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Viswanathan AN, Hankinson SE and
Schernhammer ES: Night shift work and the risk of endometrial
cancer. Cancer Res. 67:10618–10622. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schernhammer ES, Kroenke CH, Laden F and
Hankinson SE: Night work and risk of breast cancer. Epidemiology.
17:108–111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fu L and Lee CC: The circadian clock:
pacemaker and tumour suppressor. Nat Rev Cancer. 3:350–361. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dunlap JC: Molecular bases for circadian
clocks. Cell. 96:271–290. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Preitner N, Damiola F, Lopez-Molina L,
Zakany J, Duboule D, Albrecht U and Schibler U: The orphan nuclear
receptor REV-ERBalpha controls circadian transcription within the
positive limb of the mammalian circadian oscillator. Cell.
110:251–260. 2002. View Article : Google Scholar
|
|
10
|
Sato TK, Panda S, Miraglia LJ, Reyes TM,
Rudic RD, McNamara P, Naik KA, FitzGerald GA, Kay SA and Hogenesch
JB: A functional genomics strategy reveals Rora as a component of
the mammalian circadian clock. Neuron. 43:527–537. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gery S, Gombart AF, Yi WS, Koeffler C,
Hofmann WK and Koeffler HP: Transcription profiling of C/EBP
targets identifies Per2 as a gene implicated in myeloid leukemia.
Blood. 106:2827–2836. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Winter SL, Bosnoyan-Collins L, Pinnaduwage
D and Andrulis IL: Expression of the circadian clock genes Per1 and
Per2 in sporadic and familial breast tumors. Neoplasia. 9:797–800.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL,
Lin SF and Chang JG: Abnormal expression of period 1 (PER1) in
endometrial carcinoma. J Pathol. 206:111–120. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pogue-Geile KL, Lyons-Weiler J and
Whitcomb DC: Molecular overlap of fly circadian rhythms and human
pancreatic cancer. Cancer Lett. 243:55–57. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu L, Pelicano H, Liu J, Huang P and Lee
C: The circadian gene period2 plays an important role in tumor
suppression and DNA damage response in vivo. Cell. 111:41–50. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gery S, Komatsu N, Baldjyan L, Yu A, Koo D
and Koeffler HP: The circadian gene per1 plays an important role in
cell growth and DNA damage control in human cancer cells. Mol Cell.
22:375–382. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hua H, Wang Y, Wan C, Liu Y, Zhu B, Wang
X, Wang Z and Ding JM: Inhibition of tumorigenesis by intratumoral
delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene
Ther. 14:815–818. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oda A, Katayose Y, Yabuuchi S, Yamamoto K,
Mizuma M, Shirasou S, Onogawa T, Ohtsuka H, Yoshida H, Hayashi H,
Rikiyama T, Kim H, Choe Y, Kim K, Son H, Motoi F, Egawa S and Unno
M: Clock gene mouse period2 overexpression inhibits growth of human
pancreatic cancer cells and has synergistic effect with cisplatin.
Anticancer Res. 29:1201–1209. 2009.PubMed/NCBI
|
|
19
|
King DP, Zhao Y, Sangoram AM, Wilsbacher
LD, Tanaka M, Antoch MP, Steeves TD, Vitaterna MH, Kornhauser JM,
Lowrey PL, Turek FW and Takahashi JS: Positional cloning of the
mouse circadian clock gene. Cell. 89:641–653. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng ZL, Wu MW, Sun J, Sun YL, Cai YC,
Huang YJ and Xian LJ: Effects of the biological clock gene Bmal1 on
tumour growth and anti-cancer drug activity. J Biochem.
148:319–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim EM, Kim J, Park JK, Hwang SG, Kim WJ,
Lee WJ, Kang SW and Um HD: Bcl-w promotes cell invasion by blocking
the invasion-suppressing action of Bax. Cell Signal. 24:1163–1172.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lehman TA, Bennett WP, Metcalf RA, Welsh
JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR,
Gerwin BI and Harris CC: p53 mutations, ras mutations, and p53-heat
shock 70 protein complexes in human lung carcinoma cell lines.
Cancer Res. 51:4090–4096. 1991.PubMed/NCBI
|
|
23
|
Soussi T, Dehouche K and Béroud C: p53
website and analysis of p53 gene mutations in human cancer: forging
a link between epidemiology and carcinogenesis. Hum Mutat.
15:105–113. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roberson RS, Kussick SJ, Vallieres E, Chen
SY and Wu DY: Escape from therapy-induced accelerated cellular
senescence in p53-null lung cancer cells and in human lung cancers.
Cancer Res. 65:2795–2803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shukla S, Maclennan GT, Hartman DJ, Fu P,
Resnick MI and Gupta S: Activation of PI3K-Akt signaling pathway
promotes prostate cancer cell invasion. Int J Cancer.
121:1424–1432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS,
Choi KM and Um HD: Bcl-w promotes gastric cancer cell invasion by
inducing matrix metalloproteinase-2 expression via phosphoinositide
3-kinase, Akt, and Sp1. Cancer Res. 66:4991–4995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bae IH, Yoon SH, Lee SB, Park JK, Ho JN
and Um HD: Signaling components involved in Bcl-w-induced migration
of gastric cancer cells. Cancer Lett. 277:22–28. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kong D and Yamori T: Advances in
development of phosphatidylinositol 3-kinase inhibitors. Curr Med
Chem. 16:2839–2854. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cory S and Adams JM: The Bcl-2 family:
regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee HW, Lee SS, Lee SJ and Um HD: Bcl-w is
expressed in a majority of infiltrative gastric adenocarcinomas and
suppresses the cancer cell death by blocking stress-activated
protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res.
63:1093–1100. 2003.
|
|
31
|
Hoelzinger DB, Mariani L, Weis J, Woyke T,
Berens TJ, McDonough WS, Sloan A, Coons SW and Berens ME: Gene
expression profile of glioblastoma multiforme invasive phenotype
points to new therapeutic targets. Neoplasia. 7:7–16. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen-Goodspeed M and Lee CC: Tumor
suppression and circadian function. J Biol Rhythms. 22:291–298.
2007. View Article : Google Scholar
|
|
33
|
Mazzoccoli G, Panza A, Valvano MR, Palumbo
O, Carella M, Pazienza V, Biscaglia G, Tavano F, Di Sebastiano P,
Andriulli A and Piepoli A: Clock gene expression levels and
relationship with clinical and pathological features in colorectal
cancer patients. Chronobiol Int. 28:841–851. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Muller PA, Vousden KH and Norman JC: p53
and its mutants in tumor cell migration and invasion. J Cell Biol.
192:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
